Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Noel A. Powell is active.

Publication


Featured researches published by Noel A. Powell.


Bioorganic & Medicinal Chemistry Letters | 2012

Novel and selective spiroindoline-based inhibitors of sky kinase

Noel A. Powell; Jeffrey T. Kohrt; Kevin J. Filipski; Michael Kaufman; Derek James Sheehan; Jeremy E. Edmunds; Amy Delaney; Yuli Wang; Francis Bourbonais; Doh-Yeel Lee; Frank Schwende; Fang Sun; Pat McConnell; Cornel Catana; Huifen Chen; Jeff Ohren; Lisa A. Perrin

We report the discovery of a novel series of spiroindoline-based inhibitors of Sky kinase that bind in the ATP-binding site and exhibit high levels of kinome selectivity through filling the Ala571-subpocket. These inhibitors exhibit moderate oral bioavailability in the rat due to low absorption across the gut wall.


Bioorganic & Medicinal Chemistry Letters | 2013

Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ

Agustin Casimiro-Garcia; Ronald J. Heemstra; Christopher F. Bigge; Jing Chen; Fred A. Ciske; Jo Ann Davis; Teresa Ellis; Nadia Esmaeil; Declan Flynn; Seungil Han; Mehran Jalaie; Jeffrey F. Ohren; Noel A. Powell

Identification of a series of imidazo[4,5-c]pyridin-4-one derivatives that act as dual angiotensin II type 1 (AT1) receptor antagonists and peroxisome proliferator-activated receptor-γ (PPARγ) partial agonists is described. Starting from a known AT1 antagonist template, conformational restriction was introduced by incorporation of an indane ring that when combined with appropriate substitution at the imidazo[4,5-c]pyridin-4-one provided novel series 5 possessing the desired dual activity. The mode of interaction of this series with PPARγ was corroborated through the X-ray crystal structure of 12b bound to the human PPARγ ligand binding domain. Modulation of activity at both receptors through substitution at the pyridone nitrogen led to the identification of potent dual AT1 antagonists/PPARγ partial agonists. Among them, 21b was identified possessing potent dual pharmacology (AT1 IC(50) = 7 nM; PPARγ EC(50) = 295 nM, 27% max) and good ADME properties.


Bioorganic & Medicinal Chemistry Letters | 2013

Optimization of highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.

Noel A. Powell; Jennifer K. Hoffman; Fred L. Ciske; Jeffrey T. Kohrt; Sangita M. Baxi; Yun-Wen Peng; Min Zhong; Cornel Catana; Jeff Ohren; Lisa A. Perrin; Jeremy J. Edmunds

Optimization of the ADME properties of a series of 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase resulted in the identification of highly selective compounds with properties suitable for use as in vitro and in vivo tools to probe the effects of Sky inhibition.


Bioorganic & Medicinal Chemistry Letters | 2013

Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.

Noel A. Powell; Jennifer K. Hoffman; Fred L. Ciske; Michael Kaufman; Jeffrey T. Kohrt; John Quin; Derek James Sheehan; Amy Delaney; Sangita M. Baxi; Cornel Catana; Patrick McConnell; Jeff Ohren; Lisa A. Perrin; Jeremy J. Edmunds

We report the SAR around a series of 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase. 2-Aminophenethyl analogs demonstrate excellent potency but moderate kinase selectivity, while 2-aminobenzyl analogs that fill the Ala571 subpocket exhibit good inhibition activity and excellent kinase selectivity.


Journal of the American Chemical Society | 2004

Total Synthesis of Formamicin

Timothy B. Durham; Nicolas Blanchard; Brad M. Savall; Noel A. Powell; William R. Roush


Bioorganic & Medicinal Chemistry | 2007

Rational design of 6 -(2,4 -diaminopyrimidinyl ) -1,4 -benzoxazin -3-ones as small molecule renin inhibitors

Noel A. Powell; Fred L. Ciske; Cuiman Cai; Daniel D. Holsworth; Ken Mennen; Chad A. Van Huis; Mehran Jalaie; Jacqueline E. Day; Michelle Mastronardi; Pat McConnell; Igor Mochalkin; Erli Zhang; Michael J. Ryan; John W. Bryant; Wendy Collard; Suzie Ferreira; Chungang Gu; Roxane Collins; Jeremy J. Edmunds


Analytical Biochemistry | 2007

Binding thermodynamics of substituted diaminopyrimidine renin inhibitors.

Ronald W. Sarver; Jeanette Peevers; Wayne L. Cody; Fred L. Ciske; Jim Dyer; S. Donald Emerson; Jeanne C. Hagadorn; Daniel D. Holsworth; Mehran Jalaie; Michael Kaufman; Michelle Mastronardi; Patrick McConnell; Noel A. Powell; John Quin; Chad A. Van Huis; Erli Zhang; Igor Mochalkin


Bioorganic & Medicinal Chemistry Letters | 2006

Ketopiperazine-Based Renin Inhibitors: Optimization of the "C" Ring

Daniel D. Holsworth; Cuiman Cai; Xue-Min Cheng; Wayne L. Cody; Dennis M. Downing; Noe Erasga; Chitase Lee; Noel A. Powell; Jeremy J. Edmunds; Michael Andrew Stier; Mehran Jalaie; Erli Zhang; Pat McConnell; Michael J. Ryan; John W. Bryant; Tingsheng Li; Aparna Kasani; Eric Hall; Rajendra Subedi; Mohammad Rahim; Samarendra N. Maiti


Bioorganic & Medicinal Chemistry | 2005

Discovery of novel non-peptidic ketopiperazine-based renin inhibitors.

Daniel D. Holsworth; Noel A. Powell; Dennis M. Downing; Cuiman Cai; Wayne L. Cody; J. Michael Ryan; Robert Ostroski; Mehran Jalaie; John W. Bryant; Jeremy J. Edmunds


Organic Letters | 2001

Studies on the total synthesis of formamicin: synthesis of the C(1)-C(11) fragment.

Noel A. Powell; William R. Roush

Collaboration


Dive into the Noel A. Powell's collaboration.

Researchain Logo
Decentralizing Knowledge